Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?

References

• Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood92(12), 4491–4508 (1998).
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Frödin J-E, Trotta PP, Mellstedt H. Cytotoxicity of white blood cells activated by granulocyte–macrophage colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol. Immunother.39(4), 254–262 (1994).
   PubMed Web of Science ®Google Scholar
• Fischer H-G, Frosch S, Reske K, Reske-Kunz AB. Granulocyte–macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J. Immunol.141(11), 3882–3888 (1988).
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med.179(4), 1109–1118 (1994).
   PubMed Web of Science ®Google Scholar
• Young JW, Szabolcs P, Moore MAS. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit ligand and yield pure dendritic cell colonies in the presence granulocyte/macrophage colony-stimulating factor plus tumor necrosis factor α. J. Exp. Med.182(4), 1111–1119 (1995).
   PubMed Web of Science ®Google Scholar
• Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-α cooperate in the generation of dedritic Langerhans cells. Nature360(6401), 258–261 (1992).
   PubMed Web of Science ®Google Scholar
• Al-Aoukaty A, Giaid A, Maghazachi AA et al. Priming effects of granulocyte–macrophage colony-stimulating factor are coupled to cholera toxin-sensitive guanine nucleotide binding protein in human T lymphocytes. Blood83(5), 1299–1309 (1994).
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Rivoltini L et al. Opposite immune functions of GM-CSF administered as a vaccine adjuvant in cancer patients. Ann. Oncol.18(2), 226–232 (2007).
   PubMed Web of Science ®Google Scholar
• Spitler LE, Grossbard ML, Ernstoff MS et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte–macrophage colony-stimulating factor. J. Clin. Oncol.18(8), 1614–1621 (2000).
   PubMed Web of Science ®Google Scholar
• Rini BI, Fong L, Small EJ et al. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte–macrophage colony-stimulating factor. J. Urol.175, 2087–2091 (2006).
   PubMed Web of Science ®Google Scholar
• Soiffer R, Hodi FS, Dranoff G et al. Vaccination with irradiated autologous melanoma cells engineered to secrete granulocyte–macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol.21, 3343–3350 (2003).
   PubMed Web of Science ®Google Scholar
• Emens LA, Asquith JM, Jaffee EM et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogenic granulocyte–macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J. Clin. Oncol.35, 5911–5918 (2009).
   Google Scholar
• Laheru D, Lutz E, Jaffee E et al. Allogenic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin. Cancer Res.14(5), 1455–1463 (2008).
   PubMed Web of Science ®Google Scholar
• Peoples GE, Holmes JP, Hueman MT et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res.14, 797–803 (2008).
   PubMed Web of Science ®Google Scholar
• Tjoa BA, Simmons SJ, Bowes VA et al. Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PMSA peptides. Prostate36, 39–44 (1998).
   PubMed Web of Science ®Google Scholar
• Urdal DL. Development history of sipuleucel-T: progress of an active immunotherapy for prostate cancer. Presented at: International Society for Biological Therapy of Cancer. Washington, DC, USA, 31 October 2009.
   Google Scholar
• Slingluff CL, Petroni GR, Chianese-Bullock KA et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin. Cancer Res.15(22), 7036–7044 (2009).
   PubMed Web of Science ®Google Scholar
• Faries MB, Hsueh EC, Morton DL et al. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogenic whole-cell melanoma vaccine. Clin. Cancer Res.15(22), 7029–7035 (2009).
   PubMed Web of Science ®Google Scholar
• Von Meheren M, Arlen P, Gulley J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res.7(5), 1181–1191 (2001).
   Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Impact of cytokines administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol.163(3), 1690–1695 (1999).
   PubMed Web of Science ®Google Scholar
• Simmons SJ, Tjoa BA, Rogers M et al. GM-CSF as a systemic adjuvant in a Phase II prostate cancer vaccine trial. Prostate39(4), 291–297 (1999).
   PubMedGoogle Scholar
• Mack N, Gillessen S, Wilson SB et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand. Cancer Res.60(12), 3239–3246 (2000).
   Google Scholar
• Gillessen S, Naumov YN, Nieuwenhuis EES et al. CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte–macrophage colony-stimulating factor-dependent fashion. Proc. Natl Acad. Sci. USA100(15), 8874–8879 (2003).
   PubMed Web of Science ®Google Scholar
• Serafani P, De Santo C, Marigo I et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother.53(2), 64–72 (2004).
   Google Scholar
• Serafani P, Carbley R, Noonan K et al. High-dose granulocyte–macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment myeloid suppressor cells. Cancer Res.64(17), 6337–6343 (2004).
   Google Scholar
• Filipazzi P, Velanti R, Huber V et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients modulated by a granulocyte–macrophage colony-stimulating factor-based antitumor vaccine. J. Clin. Oncol.25(18), 2546–2553 (2007).
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C, Schmittel A, Keilholz U et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte–macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother.23, 275–281 (2000).
   PubMed Web of Science ®Google Scholar
• Ullenhag GJ, Frodin J-E, Mosolitis S et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA(ALVAC-KSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response. Clin. Cancer Res.9, 2447–2456 (2003).
   PubMed Web of Science ®Google Scholar
• Ullenhag GJ, Frodin J-E, Jeddi-Tehrani M et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune response in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin. Cancer Res.10, 3273–3281 (2004).
   PubMed Web of Science ®Google Scholar
• Gjersten MK, Buanes T, Rosseland AR et al. Intradermal Ras peptide vaccination with granulocyte–macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer.92, 441–450 (2001).
   Google Scholar
• Dillman RO, Wiemann M, Nayek SK et al. Interferon-γ or granulocyte–macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized Phase 2 trial of the cancer biotherapy research group. J. Immunother.26, 367–373 (2003).
   PubMed Web of Science ®Google Scholar
• Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte–macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol.23, 720–731 (2005).
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Potter DM, Belani CP et al. Randomized trial of influenza vaccine with granulocyte–macrophage colony-stimulating factor or placebo in cancer patients. J. Clin. Oncol.20, 4313–4318 (2002).
   Google Scholar
• Schwaab T, Tretter CPG, Ernstoff MS et al. Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte macrophage-colony stimulating factor (GM-CSF). Prostate66, 667–674 (2006).
   PubMed Web of Science ®Google Scholar
• Urba WJ, Nemunaitis J, Small EJ et al. Treatment of biochemical recurrence of prostate cancer with granulocyte–macrophage colony-stimulating factor secreting, allogenic, cellular immunotherapy. J. Urol.180, 2011–2018 (2008).
   Google Scholar
• Ho VT, Vonnemon M, Soiffer R et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogenic stem cell transplantation. Proc. Natl Acad. Sci. USA106, 37 (2009).
   Google Scholar
• Salgia R, Lynch T, Dranoff G et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte–macrophage colony-stimulating factor augments antitumor immunity with metastatic non-small cell lung carcinoma. J. Clin. Oncol.21(4), 586–587 (2003).
   Google Scholar
• Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol.20, 2624–2632 (2002).
   PubMed Web of Science ®Google Scholar
• Staehler M, Stenzel A, Dietrich PY et al. A Phase I study to evaluate the safety, immunogenicity and anti-tumor activity of the multi-peptide vaccine IMA901 in renal cell caricinoma patients. J. Clin. Oncol.25, 5098 (2007).
   Google Scholar
• Pilla L, Patuzzo R, Rivoltini L et al. A Phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients. Cancer Immunol. Immunother.55, 958–968 (2005).
   Google Scholar